In response to high drug prices, the Canadian government amended the country's patent act in 1969 to allow for compulsory licensing to import pharmaceuticals. As a result of the legislation, by 1983 drug costs in Canada were over $200 million lower than they would otherwise have been. The multinational drug industry was strongly opposed to compulsory licensing, despite any evidence that its economic position had been harmed. Restoration of patent protection for drugs was one of the key U.S. demands during free-trade negotiations between Canada and the United States in 1985–1987. The result was Bill C-22, which gave new drugs protection from compulsory licensing for seven to ten years. This article analyzes the impact of Bill C-22 on the generic industry, the creation of jobs in research and development, drug prices, and research and development expenditures. It concludes with an examination of future demands from the pharmaceutical industry.
Get full access to this article
View all access options for this article.
References
1.
ShulmanS. R., and RichardB. W.The 1987 Canadian patent law amendments: Revised pharmaceutical compulsory licensing provisions. Food Drug Cosmetic Law J.43: 745–757, 1988.
2.
GoreckiP. K.Regulating the Price of Prescription Drugs in Canada: Compulsory Licensing, Product Selection, and Government Reimbursement Programmes. Technical Report No. 8. Economic Council of Canada, Ottawa, 1981.
3.
Restrictive Trade Practices Commission. Report Concerning the Manufacture, Distribution and Sale of Drugs. Queen's Printer, Ottawa, 1963.
4.
Royal Commission on Health Services. Report. Queen's Printer, Ottawa, 1964.
5.
Canada, House of Commons. Second (Final) Report of the Special Committee of the House of Commons on Drug Costs and Prices. Queen's Printer, Ottawa, 1967.
6.
LangR. W.The Politics of Drugs. Saxon House, Westmead, England, 1974.
7.
Commission of Inquiry on the Pharmaceutical Industry. Report. Supply and Services Canada, Ottawa, 1985.
8.
SawatskyJ., and CashoreH.Inside dope. This Magazine, August/September 1986, pp. 4–12.
9.
JohnsonJ. B.Speech at annual general meeting of the Canadian Drug Manufacturers Association, Toronto, June 12, 1991.
10.
McQuaigL.The Quick and the Dead. Viking, Toronto, 1991.
11.
CraneD.Drug bill concessions seem tied to trade talks. Toronto Star, December 7, 1986, p. B1.
12.
AndreH.Notes for opening remarks to legislative committee on Bill C-22 by the Honourable Harvie Andre, Minister of Consumer and Corporate Affairs Canada, House of Commons, December 16, 1986.
13.
HowardR.MPs say Tories made deal on drug bill. Globe and Mail, October 16, 1987, p. A13.
14.
AuerbachS.U.S. bowed to Canadian demands to change pact. Washington Post, October 17, 1987, p. G2.
15.
LewingtonJ.Drug-patent bill not enough to satisfy U.S. on free trade. Globe and Mail, August 13, 1987, p. A1.
16.
CoteM.Notes for remarks by the Honourable Michel Cote, Minister of Consumer and Corporate Affairs, for a press statement, June 27, 1986.
17.
Canadian Drug Manufacturers Association. Submission to the Legislative Committee on Bill C-22. January 1987.
18.
BroganT., and TrepanierC.Survey of Generic Drug Manufacturers. Bureau of Policy Coordination, Consumer and Corporate Affairs Canada, Ottawa, May 1983.
19.
Generics 23% of all Canadian scripts. Scrip, No. 1646/47, August 28/30, 1991, p. 19.
20.
MaserP.‘High quality’ jobs for drug industry include cleaners. Montreal Gazette, December 17, 1986, p. B1.
21.
Legislative Committee on Bill C-22. Minutes of Proceedings and Evidence of the Legislative Committee on Bill C-22, No. 3, January 20. Supply and Services Canada, Ottawa, 1987.
22.
Statistics Canada. Industry Research and Development Statistics. Supply and Services Canada, Ottawa, various years.
23.
SpurgeonD.Brand name drug companies appear to hold winning hand in GATT talks. Can. Med. Assoc. J.146: 1429–1433, 1992.
24.
Canadian Drug Manufacturers Association. The Straight Facts. No. 4, July/August 1991.
25.
Cyanamid Canada closing ends 240 jobs. Globe and Mail, March 6, 1992, p. B3.
26.
Patented Medicine Prices Review Board. Guidelines: Excessive price. Bulletin, No. 1, July 1988.
27.
Patented Medicine Prices Review Board. Supplementary guidelines: Excessive price. Bulletin, No. 3, July 1989.
28.
Statistics Canada. Consumer Prices and Price Indexes. Supply and Services Canada, Ottawa, various years.
29.
Statistics Canada. Industry Price Indexes. Supply and Services Canada, Ottawa, various years.
30.
Patented Medicine Prices Review Board. Third Annual Report for the Year Ended December 31, 1990. Supply and Services Canada, Ottawa, 1991.
31.
Nova Scotia Royal Commission on Health Care. Towards a New Strategy. Halifax, 1989.
32.
Pharmaceutical Inquiry of Ontario. Prescriptions for Health. Toronto, 1990.
33.
PsutkaD., Assistant Deputy Minister, Emergency and Special Health Services. Brief to the Senate Committee on the Patent Act, Toronto, June 10, 1987.
34.
CohenL.The aftermath of Bill C-22. Pharmacy Pract. 7(1): 28–34, 1991.
35.
Globe and Mail, August 10, 1991, p. A3.
36.
Canadian Drug Manufacturers Association. The Straight Facts, No. 5, September 1991.
37.
TaylorK. M.The impact of the pharmaceutical industry's clinical research programs on medical education, practice and researchers in Canada: A discussion paper. In Canadian Pharmaceutical Research and Development: Four Short-term Studies. Industry, Science & Technology Canada, Ottawa, 1991.
38.
BurstallM. L.DunningJ. H., and LakeA.Multinational Enterprises, Governments and Technology—The Pharmaceutical Industry. OECD, Paris, 1981.
39.
Patented Medicine Prices Review Board. Second Annual Report 1990. Supply and Services Canada, Ottawa, 1990.
40.
Brogan Consulting. Analysis of investment in Canadian-based pharmaceutical research and development. In Canadian Pharmaceutical Research and Development: Four Short-term Studies. Industry, Science & Technology Canada, Ottawa, 1991.
41.
GilmanJ. P. W.Impact of pharmaceutical company sponsored research on basic research at Canadian universities—A preliminary analysis. In Canadian Pharmaceutical Research and Development: Four Short-term Studies. Industry, Science & Technology Canada, Ottawa, 1991.
42.
Single North American market soon?Scrip, No. 1572, December 5, 1990, p. 17.
43.
PMA pessimistic about GATT. Scrip, No. 1661, October 18, 1991, p. 19.
44.
The House. CBC-AM, October 5, 1991.
45.
McCarthyS.Big drug firms likely to win in GATT deal. Toronto Star, December 6, 1991, p. B3.
46.
MickleburghR.Generic drugs in danger, group says. Globe and Mail, December 18, 1991, pp. A1, A2.
47.
McCarthyS.Move on drug patents sparks fear of price rises. Toronto Star, January 19, 1992, p. B4.
48.
GhersonG.Ottawa's new drug patent plan. Financial Times of Canada, January 27, 1992, p. 9.
49.
Mexican patent law abolished. Scrip, No. 1631, July 5, 1991, p. 17.
